Document and Entity Information Statement [Table] Statement [Line Items] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Condensed Balance Sheets Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Accounts Receivable, Net, Current Accounts receivable, net of allowance of $131 and $117 as of March 31, 2016 and December 31, 2015, respectively Inventory, Net Supplies inventory Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Restricted Cash and Cash Equivalents, Current Restricted cash Cash reserved to cover liabilities associated with Merger Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Finite-Lived Intangible Assets, Net Finite-lived intangible assets, net Goodwill Restricted Cash and Cash Equivalents, Noncurrent Restricted cash Long term deposit consisting of letter of credit serving as security for lease Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Outstanding obligations Accrued Liabilities, Current Accrued liabilities Total accrued liabilities Deferred Revenue, Current Deferred Genzyme co-promotion fee Liabilities, Current Total current liabilities Long-term Debt, Excluding Current Maturities Long-term debt Deferred Rent Credit, Noncurrent Deferred rent, net of current portion Liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued. Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of March 31, 2016 and December 31, 2015 Common Stock, Value, Issued Common stock, $0.001 par value; 125,000,000 shares authorized, 27,858,317 and 27,685,291 shares issued and outstanding as of March 31, 2016 and December 31, 2015, respectively Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Allowance for Doubtful Accounts Receivable, Current Accounts receivable, allowance (in dollars) Allowance for doubtful accounts Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Condensed Statements of Operations and Comprehensive Loss Revenue, Net Revenue Total Operating Expenses [Abstract] Operating expenses: Cost of Revenue. Cost of revenue Research and Development Expense Research and development Selling and Marketing Expense Selling and marketing General and Administrative Expense General and administrative Amortization of Intangible Assets Intangible asset amortization Costs and Expenses Total operating expenses Operating Income (Loss) Loss from operations Interest Expense Interest expense Interest expense Other Nonoperating Income (Expense) Other income (expense), net Net Income (Loss) Available to Common Stockholders, Basic Net loss Net loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Earnings Per Share, Basic and Diluted Net loss per common share, basic and diluted (in dollars per share) Weighted Average Number of Shares Outstanding, Basic and Diluted Shares use to compute net loss per common share, basic and diluted (in shares) Condensed Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Provision for Doubtful Accounts Bad debt expense Recognition of Deferred Revenue Genzyme co-promotion fee amortization Amortization of up-front co-promotion fee Share-based Compensation Stock-based compensation Amortization of Financing Costs and Discounts Amortization and write-off of debt discount and issuance costs Represents the amount of interest end of term payment of debt. Debt instrument end of term payment interest amount Interest on debt balloon payment and prepayment penalty End-of-term payment interest Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories Supplies inventory Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Other Noncurrent Assets Other assets Increase (Decrease) in Accounts Payable Accounts payable The increase (decrease) during the reporting period in the amount of expenses incurred but not yet paid and deferred rent. Increase (Decrease) in Accrued Liabilities and Deferred Rent Accrued liabilities and deferred rent Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Investing activities Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Increase (Decrease) in Restricted Cash Change in restricted cash Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Financing activities Proceeds from Issuance of Long-term Debt Proceeds from the issuance of long-term debt, net of debt issuance costs Repayments of Long-term Debt Payment of long-term debt Repayment of long-term debt The cash outflow for the payment of the end-of-term obligation and prepayment penalty. Payment of End of Term Obligation Payment of end-of-term debt obligation and prepayment penalty Proceeds from Stock Options Exercised Proceeds from the exercise of common stock options and employee stock purchases Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities Net Cash Provided by (Used in) Continuing Operations Net increase (decrease) in cash and cash equivalents Supplemental Cash Flow Information [Abstract] Supplementary cash flow information of non cash investing and financing activities: Future cash outflow (inflow) to pay for purchases of fixed assets that have occurred. Capital Expenditures Incurred But Not Yet Paid Net Purchases of property and equipment included in accounts payable and accrued liabilities Amount of deferred stock offering costs not yet paid. Deferred Stock Offering Costs Unpaid deferred debt issuance costs Organization and Description of Business Business Description and Basis of Presentation [Text Block] Organization and Description of Business Net Loss Per Common Share Earnings Per Share [Text Block] Net Loss Per Common Share Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Liabilities Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Debt Debt Disclosure [Text Block] Debt Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Stock Incentive Plans Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock Incentive Plans Genzyme Co-promotion Agreement Collaborative Arrangement Disclosure [Text Block] Genzyme Co-promotion Agreement Thyroid Cytopathology Partners Long-term Contracts or Programs Disclosure [Text Block] Thyroid Cytopathology Partners Income Taxes Income Tax Disclosure [Text Block] Income Taxes Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Use of Estimates, Policy [Policy Text Block] Use of Estimates Disclosure of accounting policy for concentrations of credit risk and other risks and uncertainties. Concentrations of Credit and Other Risks and Uncertainties [Policy Text Block] Concentrations of Credit Risk and Other Risks and Uncertainties Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Restricted Cash Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] Allowance for Doubtful Accounts Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Revenue Recognition, Policy [Policy Text Block] Revenue Recognition New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Concentration Risk [Table] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Customer Concentration Risk [Member] Revenue concentration risk Credit Concentration Risk [Member] Gross receivables concentration risk Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Accounts Receivable [Member] Accounts receivable Concentration Risk [Line Items] Concentrations of Credit Risk and Other Risks and Uncertainties Concentration Risk No definition available. Concentrations of Credit Risk and Other Risks and Uncertainties Concentrations of Credit Risk and Other Risks and Uncertainties Concentration Risk Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Schedule of the Company's third-party payers as a percentage of total Revenue Recognition [Abstract] Revenue Recognition Tabular disclosure of recognition of revenue when cash is received and on an accrual basis. Schedule of Revenue Recognition, Cash and Accrual Basis [Table Text Block] Schedule of Revenue recognized when cash is received and on an accrual basis Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued liabilities Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of future minimum lease payments under non-cancelable operating leases Schedule of Debt [Table Text Block] Schedule of net debt obligation Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Schedule of future principal payments under the Credit agreement Interest Income and Interest Expense Disclosure [Table Text Block] Schedule of interest expense on debt Tabular disclosure of number of common shares reserved for future issuance. Schedule of Common Stock Capital Shares Reserved for Future Issuance [Table Text Block] Schedule of reserved shares of common stock for issuance Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock incentive plans Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of activity under the Company's stock option plans Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Summary of stock-based compensation expense Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of assumptions used to calculate estimated grant date fair value of stock options using the Black-Scholes option-pricing valuation model Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Schedule of grant date fair value of the ESPP shares was calculated using Black Scholes option Number of Operating Segments Number of operating segments Revenue from sale of goods and services rendered, in the normal course of business, before deducting sales returns and allowances, and sales discounts, when it serves as a benchmark in a concentration of risk calculation. Sales Revenue Gross [Member] Revenue Health Care Organization, Revenue Sources [Axis] Health Care Organization Revenue Sources [Domain] Health Care Organization, Revenue Sources [Domain] Represents information pertaining to Medicare, a significant third-party payer. Medicare [Member] Medicare Represents information pertaining to Aetna, a significant third-party payer. Aetna [Member] Aetna Represents information pertaining to Cigna, a significant third-party payer. Cigna [Member] Cigna Represents information pertaining to United Healthcare, a significant third-party payer. United Healthcare [Member] United Healthcare Represents the number of major financial institutions, with which cash and cash equivalents are deposited by the entity. Number of Major Financial Institutions with which Cash and Cash Equivalents Deposited Number of major financial institutions with which the company's cash and cash equivalents are deposited Concentration Risk, Percentage Concentrations of credit risk (as a percent) Schedule of Cash and Cash Equivalents [Table] Cash and Cash Equivalents [Line Items] Restricted Cash and Investments [Abstract] Restricted Cash Security Deposit Security deposit Amount held as security for lease The amount included in deposits as a pledge for corporate credit cards. Restricted Cash Corporate Credit Cards Pledge Pledge for corporate credit cards Allowance for Doubtful Accounts [Abstract] Allowance for Doubtful Accounts Allowance for Doubtful Accounts Receivable [Roll Forward] Activity of allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Write-offs Write-offs for doubtful accounts Revenue recognized during the period based on cash receipts. Revenue Recognized Received In Cash Revenue recognized when cash is received Revenue recognized during the period on an accrual basis. Revenue Recognized On Accrual Basis Revenue recognized on an accrual basis Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Total shares of common stock equivalents (in shares) Employee-related Liabilities, Current Accrued compensation expenses Accrued Marketing Costs, Current Accrued Genzyme co-promotion fees Other Accrued Liabilities, Current Accrued other Fair Value Measurements, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Fair Value Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value Measurements Recurring [Member] Recurring Fair Value, Hierarchy [Axis] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value Inputs Level1 [Member] Level I Asset Class [Axis] Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Asset Class [Domain] Money Market Funds [Member] Money market funds Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair value measurements Assets, Fair Value Disclosure Financial Assets Schedule of Operating Leased Assets [Table] Operating Leased Assets [Line Items] Operating Leases Amount of space leased under the terms of the agreement. Lessee Leasing Arrangements, Operating Leases, Space Leased Amount of space leased Amount of tenant improvement allowance granted by the lessor to a tenant under the terms of the agreement. Tenant Improvement Allowance Amount of funding provided by landlord for tenant improvements Estimated amount of improvements to assets held under a lease arrangement the entity expects to make, excluding the amount of tenant improvement allowance granted by the lessor under the terms of the agreement Leasehold Improvements, Estimate, Excluding Tenant Allowance Estimated amount of improvements expected in addition to landlord's tenant allowance Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Future minimum lease payments under non-cancelable operating leases Operating Leases, Future Minimum Payments, Remainder of Fiscal Year 2016 Operating Leases, Future Minimum Payments, Due in Two Years 2017 Operating Leases, Future Minimum Payments, Due in Three Years 2018 Operating Leases, Future Minimum Payments, Due in Four Years 2019 Operating Leases, Future Minimum Payments, Due in Five Years 2020 Operating Leases, Future Minimum Payments, Due Thereafter Thereafter Operating Leases, Future Minimum Payments Due Total minimum lease payments Operating Leases, Rent Expense, Net Facilities rent expense Purchase Obligation [Abstract] Supplies Purchase Commitments Number of suppliers with which the entity has non-cancelable purchase obligations. Number of Suppliers With Purchase Obligations Number of suppliers Purchase Obligation Non-cancelable purchase commitment Schedule of Long-term Debt Instruments [Table] Long-term Debt, Type [Axis] Longterm Debt Type [Domain] Long-term Debt, Type [Domain] Line Of Credit [Member] Credit Agreement Represents the term loans under the loan and security agreement. Term Loan [Member] Term Loans Debt Instrument [Line Items] Debt Represents the number of term loans available to the Company. Number Of Term Loans Number of term loans Line of Credit Facility, Maximum Borrowing Capacity Maximum borrowing capacity Proceeds from Lines of Credit Drawn down initial term loan Debt Instrument, Increase (Decrease), Net Amount drawn down Debt Instrument, Unused Borrowing Capacity, Amount Amount not drawn Debt Instrument, Interest Rate, Stated Percentage Interest rate (as a percent) Represents the number of installments for payment of the debt. Debt Instrument Number of Installments Number of installments Represents the term of debt with equal quarterly installments. Term Of Debt With Equal Quarterly Installments Term of debt with equal quarterly installments Rate for which Company may elect to pay interest in cash. Debt Instrument Fixed Rate Percentage Paid In Cash Rate for which Company may elect to pay interest in cash (as a percent) Percentage of interest rate for which interest is paid-in-kind by adding paid-in-kind interest to the outstanding principal amounts of the Term Loans. Debt Instrument Interest Paid-In-Kind Percentage Remaining percentage for which interest is paid-in-kind Amount of prepayment allowed under the current agreement. Debt Instrument Minimum Prepayment Allowed Prepayment allowed The whole multiple for which payments must be made in excess of minimum prepayment. Debt Instrument Prepayment Amount Excess Multiple Whole multiple in excess of minimum prepayment Represents the period after the date of borrowing in which the debt is repayable under the agreement. Debt Instrument Period after which Debt is Repayable Period after which debt is repayable Represents the percentage of prepayment premium for prepayment made on or prior to March 31, 2018. Debt Instrument Penalty Percentage On Prepayment Period One Prepayment premium for prepayment made on or prior to March 31, 2018 (as a percent) Represents the percentage of prepayment premium for prepayment after March 31, 2018 and on or prior to March 31, 2019. Debt Instrument Penalty Percentage On Prepayment Period Two Prepayment premium for prepayment made after March 31, 2018 and on or prior to March 31, 2019 (as a percent) Represents the percentage of prepayment premium for prepayment after March 31, 2019 and on or prior to March 31, 2020. Debt Instrument Penalty Percentage On Prepayment Period Three Prepayment premium for prepayment made after March 31, 2019 and on or prior to March 31, 2020 (as a percent) Represents the percentage of prepayment premium for prepayment after March 31, 2020 and on or prior to March 31, 2021. Debt Instrument Penalty Percentage On Prepayment Period Four Prepayment premium for prepayment made after March 31, 2020 and on or prior to March 31, 2021 (as a percent) Represents the percentage of prepayment premium for prepayment after March 31, 2021. Debt Instrument Penalty Percentage On Prepayment Period Five Prepayment premium for prepayment made after March 31, 2021 (as a percent) Represents the percentage of prepayment penalties for prepayment within one year of the loan origination. Debt Instrument Penalty Percentage on Prepayment within One Year of Origination Prepayment penalties for prepayment within one year of the loan origination (as a percent) Represents the percentage of prepayment penalties for prepayment within two years of the loan origination. Debt Instrument Penalty Percentage on Prepayment within Two Years of Origination Prepayment penalties for prepayment within two years of the loan origination (as a percent) Represents the percentage of prepayment penalties for prepayment after two years of the loan origination. Debt Instrument Penalty Percentage on Prepayment after Two Years of Origination Prepayment penalties for prepayment after two years of the loan origination (as a percent) Represents the number of tranches for a term loan. Number of Tranches Number of tranches Proceeds from (Repayments of) Debt Repayment of debt Interest Paid Cash paid for interest on debt Payments of Debt Extinguishment Costs End-of term payment Amount of prepayment premium waived. Debt Instrument, Prepayment Premium Amount of prepayment premium waived Represents the amount of obligation for the end of term payment as of the balance sheet date. Debt Instrument End of Term Payment Amount Amount of end of term payment Amount of third party fees paid in connection with loan agreement. Debt Instrument, Third Party Fee, Amount Paid Third-party fees paid The period for which the lender has the right to participate in certain future equity financings of the Company. Debt Instrument Period For Which Rights Equity Financings Period for which lender has rights to participate in equity financings The amount for which lender can participate in future equity financings. Debt Instrument Future Equity Financings Amount Maximum amount allowed to participate in future equity financings Debt Instrument, Face Amount Debt principal Debt Instrument, Unamortized Discount Deferred debt issuance costs Long-term Debt Net debt obligation Amortization of Financing Costs Amortization of deferred debt issuance costs Future principal payments under the Amended Loan Future principal payments Long-term Debt, Maturities, Repayments of Principal in Year Five 2020 Long-term Debt, Maturities, Repayments of Principal after Year Five Thereafter Long-term Debt, Gross Total Interest expense on debt Interest Expense, Debt, Excluding Amortization Nominal interest Amortization of Debt Discount (Premium) Amortization and write-off of debt discount and debt issuance costs Prepayment penalty. Prepayment Penalty Prepayment penalty Interest Expense, Debt Total Schedule of Stock by Class [Table] Class of Stock [Line Items] No definition available. Common Stock [Abstract] Common Stock Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Balance at the end of the period (in shares) Balance at beginning of the period (in shares) Options issued and outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Balance at the end of the period (in shares) Balance at the beginning of the period (in shares) Shares available for issuance Common Stock, Capital Shares Reserved for Future Issuance Total number of shares reserved for issuance Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Available for Grant [Roll Forward] Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Additional options authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted (in shares) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Canceled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Stock Options Outstanding The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period 1 Canceled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Options vested and exercisable at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Options vested and expected to vest at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Balance at the end of the period (in dollars per share) Balance at beginning of the period (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Canceled (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Options vested and exercisable at the end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Options vested and expected to vest at the end of the period (in dollars per share) Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Life [Abstract] Weighted Average Remaining Contractual Life Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Options vested and exercisable at the end of the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Options vested and expected to vest at the end of the period Share Based Compensation Arrangement by Share Based Payment Award Options Aggregate Intrinsic Value [Abstract] Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Balance at the end of the period (in dollars) Balance at the beginning of the period (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Options vested and exercisable at the end of the period (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Options vested and expected to vest at the end of the period (in dollars) Share Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average fair value of options to purchase common stock granted (in dollars per share) The weighted average grant-date fair value of options exercised during the reporting period. Share Based Compensation Arrangement by Share Based Payment Award Options Exercises in Period Weighted Average Grant Date Fair Value Weighted average fair value of stock options exercised (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Intrinsic value of stock options exercised (in dollars) Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Award Type [Axis] Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Equity Award [Domain] An arrangement whereby an employee or non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, excluding options granted as bonus related compensation. Employee And Non Employee Stock Option Excluding Bonus Compensation [Member] Stock-based Compensation An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, excluding options granted as bonus compensation. Employee Stock Option Excluding Bonus Compensation [Member] Stock-based Compensation, employees An arrangement whereby a non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Non Employee Stock Option [Member] Stock-based Compensation, non-employees Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Cost Of Sales [Member] Cost of revenue Research And Development Expense [Member] Research and development Selling And Marketing Expense [Member] Selling and marketing General And Administrative Expense [Member] General and administrative Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Stock-based compensation Allocated Share-based Compensation Expense Share-based compensation expense (in dollars) Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Unrecognized compensation expense (in dollars) Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Period over which unrecognized compensation expense expected to be recognized Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Assumptions used to calculate estimated fair value of stock options using the Black-Scholes option-pricing valuation model Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Weighted-average volatility, low end of range (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Weighted-average volatility, high end of range (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Weighted-average expected term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, low end of range (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free interest rate, high end of range (as a percent) Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements And Nonarrangement Transactions [Member] Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement Copromotion [Member] Co-promotion agreement Contractual arrangement involving the promotion the Company's Afirma thyroid diagnostic solution in which both the entity and its partner: (i) actively participate in the joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Collaborative Arrangement Copromotion Afirma Thyroid Diagnostic Solution [Member] Afirma thyroid diagnostic solution co-promotion agreement Contractual arrangement involving the promotion of Afirma GEC in countries other than the United States in which both the entity and its partner: (i) actively participate in the joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Collaborative Arrangement Copromotion Afirma Gec [Member] Ex-U.S. Co-Promotion Agreement Counterparty Name [Axis] Repurchase Agreement Counterparty Name [Domain] Counterparty Name [Domain] Represents information pertaining to Genzyme Corporation, a co-promoter. Genzyme Corporation [Member] Genzyme Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Accrued Liabilities [Member] Accrued liabilities Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Genzyme Co-promotion Agreement Represents the number of countries outside United States in which marketing authorization is obtained under the agreement. Collaborative Arrangement Number of Countries Outside United States in which Marketing Authorization is Obtained Number of countries outside United States for exclusive promotion under the agreement Increase (Decrease) in Deferred Revenue Co-promotion fee received from Genzyme Represents the co-promotion fees paid to co-promoter as a percentage of cash receipts under the agreement. Collaborative Arrangement Co-promotion fees percentage of cash receipts Co-promotion fees as a percentage of cash receipts Represents the amortization period of co-promotion fee. Collaborative Arrangement Co Promotion Fee Amortization Period Straight-line amortization period of co-promotion fee Balance of unamortized up-front co-promotion fee. Unamortized Up-Front Co-Promotion Fee Unamortized up-front co-promotion fee Represents the co-promotion fees paid to co-promoter as a percentage of net revenue under the agreement. Collaborative Arrangement Co-promotion Fees Percentage of Net Revenue Co-promotion fee paid as a percentage of net revenue Represents the term of the co-promotion agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Collaborative Arrangement, Term Period of agreement Represents the co-promotion fees paid to co-promoter as a percentage of cash receipts for the remaining periods under the agreement. Collaborative Arrangement Co-promotion fees percentage of cash receipts remaining periods Co-promotion fees as a percentage of cash receipts for remaining periods Represents the amount of co-promotion expenses incurred under the agreement. Collaborative Arrangement Co Promotion Expenses Co-promotion expenses Represents the amount of outstanding obligation under the agreement. Collaborative Arrangement Outstanding Obligation Outstanding obligation to Genzyme Schedule of Variable Interest Entities [Table] Variable Interest Entities [Axis] Classification Of Variable Interest Entity [Domain] Variable Interest Entity, Classification [Domain] Variable Interest Entity Not Primary Beneficiary [Member] Thyroid Cytopathology Partners Variable Interest Entity [Line Items] Thyroid Cytopathology Partners Represents the minimum period required to provide notice of intent not to renew agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Agreement Terms, Non-Renewal Notice Period Notice of intent not to renew period Testing and evaluation service costs directly related to generating revenues. Testing and Evaluation Services Expense Expenses for cytopathology testing and evaluation services Amount of reimbursement from third party for rent and related operating expenses for shared space included in other income in the income statement. Other Income Rent Reimbursement Reduction to rent expense for TCP's portion of costs for subleased space Unrecognized Tax Benefits Unrecognized tax benefit Unrecognized Tax Benefits that Would Impact Effective Tax Rate Unrecognized tax benefits, which if recognized, would affect the effective tax rate Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Interest expense or penalties related to unrecognized tax benefits Lease Arrangement, Type [Axis] Lease Arrangement Type [Domain] Lease Arrangement, Type [Domain] Represents the lease for headquarters and laboratory space in South San Francisco, California that expires March 2016. Headquarters And Laboratory Facility South San Francisco [Member] Headquarters and laboratory facility, South San Francisco, Lease expiring 2016 Represents the lease for headquarters and laboratory space in South San Francisco, California that expires March 2026. Headquarters And Laboratory Facilities South San Francisco Lease Two [Member] Headquarters and laboratory facilities, South San Francisco, Lease signed April 2015 Antidilutive Securities [Axis] Antidilutive Securities Name [Domain] Antidilutive Securities, Name [Domain] An arrangement whereby an employee or non-employee is entitled to receive in the future, subject to vesting and other restrictions, number of shares in the entity at a specified price, as defined in the agreement. Employee And Non Employee Stock Option [Member] Options Employee Stock Option [Member] Employee stock purchase plan Represents the lease for laboratory facilities in Austin, Texas that expires July 2018. Laboratory Facilities Austin Texas [Member] Laboratory facilities, Austin, Texas Other Noncurrent Assets [Member] Other assets Lender Name [Axis] Line Of Credit Facility Lender [Domain] Line of Credit Facility, Lender [Domain] Represents information pertaining to Visium Healthcare Partners, LP Visium [Member] Visium Debt Instrument [Axis] Debt Instrument Name [Domain] Debt Instrument, Name [Domain] Represents the initial term loan. Initial Term Loan [Member] Initial Term Loan Represents the second term loan. Second Term Loan [Member] Second Term Loan Represents the term loan due in June 2017. Term Loan Due2017 [Member] Term Loan Due 2017 Represents the first portion of an Amended term loan. Term Loan Tranche One [Member] Term Loan Tranche One Represents the second portion of an Amended term loan. Term Loan Tranche Two [Member] Term Loan Tranche Two Represents the third portion of an Amended term loan that may be borrowed anytime through June 30, 2016. Term Loan Tranche Three [Member] Term Loan Tranche Three Range [Axis] Range [Member] Range [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Employee Stock [Member] ESPP